Whole-body biodistribution, radiation dosimetry estimates for the pet norepinephrine transporter probe (s,s)-[f]fmener-d2 in non-human primates

Nuclear Medicine Communications

Volumn 26, Issue 8, 2005, Pages 695-700

  Seneca, Nicholas ^a   Andree, Bengt ^b   Sjoholm, Nils ^c   Schou, Magnus ^c   Pauli, Stefan ^c   Mozley, P David ^c   Stubbs, James B ^c   Liow, Jeih San ^c   Sovago, Judit ^c   Gulyás, Balazs ^c   Innis, Robert ^c   Halldin, Christer ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Radiation Dosimetry Systems   (United States)

Author keywords

Dosimetry; Norepinephrine transporter; PET; Positron emission tomography; Whole body biodistribution

Indexed keywords

FMENER D 2 F 18; NORADRENALIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEMALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; RADIATION EXPOSURE; TISSUE DISTRIBUTION; WHOLE BODY RADIATION;

ANIMALS; BODY BURDEN; BRAIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; MOLECULAR PROBE TECHNIQUES; MORPHOLINES; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS; RELATIVE BIOLOGICAL EFFECTIVENESS; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 23044465598     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000171780.72908.e7     Document Type: Article

References (25)

1. McCormick DA, Pape HC, Williamson A. Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog Brain Res 1991; 88:293-305.
2. Mazei MS, Pluto CP, Kirkbride B, Pehek EA. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 2002; 936:58-67.
3. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003; 64:110-111.
4. Goldstein DS, Brush JE, Eisenhofer G, Stull R, Esler M. In vivo measurement of neuronal uptake of norepinephrine in the human heart. Circulation 1988; 78:41-48.
5. Langer O, Halldin C. PET and SPET tracers for mapping the cardiac nervous system. Eur J Nucl Med Mol Imaging 2002; 29:416-434.
6. Melon P, Schwaiger M. Imaging of metabolism and autonomic innervation of the heart by positron emission tomography. Eur J Nucl Med 1992; 19:453-464.
7. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12:461-475.
8. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997; 17:8451-8458.
9. Tejani-Butt SM, Yang J, Zaffar H. Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease. Brain Res 1993; 631:147-150.
10. 11C]MeNER. Nucl Med Biol 2003; 30:707-714.
11. Wilson AA, Johnson DP, Mozley PD, Hussey D, Ginovart N, Nobrega J, et al. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 2003; 30:85-92.
12. Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 2003; 50:345-352.
13. Schou M, Halldin C, Sovago J, Pike VW, Hall H, Gulyas B, et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004; 53:57-67.
14. Fowler J, Wang G, Logan J, Xie S, Volkow N, MacGregor R, et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 1995; 36:1255-1262.
15. Solin O, Eskola O, Hamill TG, Bergman J, Lehikoinen P, Gronroos T, et al. Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol 2004; 6:373-384.
16. Carrio I. Cardiac neurotransmission imaging. J Nucl Med 2001; 42:1062-1076.
17. Farde L, Halldin C, Nagren K, Suhara T, Karlsson P, Schoeps KO, et al. Positron emission tomography shows high specific uptake of racemic carbon-11 labelled norepinephrine in the primate heart. Eur J Nucl Med 1994; 21:345-347.
18. 18F]fluorometaraminol: a PET radiotracer for mapping sympathetic nerves of the heart. Nucl Med Biol 2000; 27:233-238.
19. 11C-DASB determined from whole-body imaging in non-human primates. Nucl Med Commun 2004; 25:81-86.
20. Loevinger R, Watson E. MIRD Primer for Absorbed Dose Calculations. The Society of Nuclear Medicine; 1991.
21. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys 1973; 25:147-161.
22. 18F-FECNT in non human primates. Nucl Med Commun 2004; 25:737-742.
23. 18F labeled radiopharmaceuticals. J Radiat Res 1991; 32:243-261.
24. International Commission on Radiological Protection. Radiological Protection and Safety in Medicine. ICRP Publication 73. Ann ICRP 26. Oxford: Pergamon Press; 1996.
25. Guidance on Medical Exposures in Medical and Biomedical Research. Radiation Protection 99. European Commission; 1998.